Publish
Home
Live
new
RH Journal
ResearchCoin
Grants
Funding
Browse
Journals
Hubs
Tools
Lab Notebook
Beta
Reference Manager
Resources
Verify Identity
Community
Support
About
Terms
Privacy
Issues
Docs
Author
Log in
Sign up
NG
Nicola Goekbuget
Author with expertise in Epidemiology and Treatment of Childhood Leukemia
Achievements
This user has not unlocked any achievements yet.
Key Stats
Upvotes received:
0
Publications:
8
(0% Open Access)
Cited by:
0
h-index:
23
/
i10-index:
45
Reputation
Biology
< 1%
Chemistry
< 1%
Economics
< 1%
Show more
How is this calculated?
Overview
Publications
8
Peer Reviews
Comments
Grants
Publications
0
Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia
Stefan Habringer
et al.
Nov 5, 2024
Genetics
Immunology
0
Paper
Genetics
Immunology
0
Save
0
Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL
Nadine Wolgast
et al.
Nov 5, 2024
Genetics
Artificial Intelligence
0
Paper
Genetics
Artificial Intelligence
0
Save
0
Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group
Anjali Cremer
et al.
Nov 5, 2024
Immunology
Internal Medicine
0
Paper
Immunology
Internal Medicine
0
Save
0
C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL
Björn-Thore Hansen
et al.
Nov 5, 2024
Genetics
Molecular Biology
0
Paper
Genetics
Molecular Biology
0
Save
0
IDH2
Mutations from Clonal Hematopoiesis and Acquired
IKZF1
Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
Johanna Horns
et al.
Nov 5, 2024
Genetics
Immunology
0
Paper
Genetics
Immunology
0
Save
0
Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013
Nicola Goekbuget
et al.
Nov 5, 2024
Genetics
Oncology
0
Paper
Genetics
Oncology
0
Save
0
Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in
KMT2A
-Rearranged BCP-ALL
Alina Hartmann
et al.
Nov 5, 2024
Genetics
Oncology
0
Paper
Genetics
Oncology
0
Save
0
Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation
Roman Pfeifer
et al.
Nov 5, 2024
Genetics
Oncology
0
Paper
Genetics
Oncology
0
Save